What Bioenergetic Age Means for Alzheimer's Risk and Treatment

Reducing Your 'Bioenergetic Age' May Ward Off Alzheimer's, Study Finds

Alzheimer’s disease has long been thought of as a condition that primarily depends on genetics and the natural passage of time. However, a recent study suggests that you may have more control over your risk of developing Alzheimer's than you think, and a new metric could be the key: bioenergetic age.

Understanding Bioenergetic Age

Bioenergetics is the field of biochemistry that studies how living organisms generate and use energy. Bioenergetic age, as the study reveals, is not the same as chronological age. Instead, it refers to how efficiently your cells are able to generate energy. This is a crucial concept because energy metabolism plays a significant role in many aspects of health, including cognitive function. If your cells are working efficiently to produce energy, your body and brain tend to function better, which could help stave off diseases like Alzheimer’s.

The discovery of bioenergetic age is revolutionary because it suggests that people may be able to alter their risk of Alzheimer’s by improving the efficiency of their cellular energy processes, regardless of their actual age. This metric could offer a more accurate and personalized approach to assessing Alzheimer's risk.

The New Study: Bioenergetic Age and Alzheimer's

The study, led by Dr. Jan Krumsiek, a physiologist at Weill Cornell Medicine, analyzed how bioenergetic age might relate to Alzheimer’s disease progression. Researchers found that individuals with a higher bioenergetic age (meaning their cells were producing energy less efficiently) had a greater risk of developing severe Alzheimer's pathology and faster cognitive decline. In contrast, individuals with lower bioenergetic ages, despite possibly showing early signs of Alzheimer’s, demonstrated slower cognitive decline.

What does this mean for patients and clinicians? It suggests that bioenergetic age could be a valuable marker for Alzheimer's risk and help doctors better predict who is most likely to experience rapid progression of the disease.

Bioenergetic Capacity and Cognitive Resilience

In addition to bioenergetic age, researchers identified another critical concept: bioenergetic capacity. This refers to the ability of cells to maintain normal energy production even when they face pathological anomalies, such as those seen in Alzheimer’s disease. Some individuals, despite having energy pathways that are compromised, can remain relatively symptom-free. This is because their bioenergetic capacity seems to help them sustain normal cognition, even in the face of Alzheimer’s-related damage to brain cells.

This finding sheds light on the varying ways Alzheimer's progresses. Some individuals may exhibit early symptoms, such as impaired energy metabolism, but remain symptom-free for years. Others, on the other hand, show rapid cognitive decline. The difference could be linked to the bioenergetic capacity that helps some individuals maintain their cognitive abilities despite pathological changes.

The Role of Acylcarnitines in Alzheimer's Risk

So, how can we measure bioenergetic age, and how does it correlate with Alzheimer’s risk? The researchers turned to acylcarnitines, a class of fatty acid metabolites found in the blood. These metabolites have long been studied for their role in energy metabolism, and previous research has shown a connection between acylcarnitine levels and cognitive decline.

Through their analysis of data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the researchers found that higher levels of acylcarnitines were associated with a higher bioenergetic age and more severe Alzheimer’s pathology. Conversely, individuals with lower acylcarnitine levels showed slower cognitive decline—comparable to the effects of lecanemab, a drug designed to treat Alzheimer’s.

The findings suggest that lower bioenergetic age may be protective against Alzheimer’s. Those with lower acylcarnitine levels exhibited slower cognitive decline, indicating that by improving one’s bioenergetic age, it may be possible to reduce the risk of Alzheimer’s disease progression.

Repurposing Blood Tests for Bioenergetic Age

The exciting part of this discovery is that the acylcarnitine blood test, which was originally developed to detect metabolic and mitochondrial disorders in newborns, can now potentially be used to assess bioenergetic age in older adults. This test is relatively inexpensive and widely available, meaning it could be used as a simple, effective tool for early Alzheimer’s detection and personalized treatment planning.

The next step, according to the researchers, is to repurpose this technology for Alzheimer’s patients. By testing for acylcarnitine levels, doctors could identify individuals at higher risk for Alzheimer's much earlier, offering opportunities for personalized interventions. These interventions may include behavioral changes, such as improving exercise and nutrition, which could help patients lower their bioenergetic age and reduce their risk of Alzheimer’s.

Potential Interventions to Reduce Bioenergetic Age

The study shows that lifestyle interventions—particularly those focused on improving physical activity and nutrition—could help reduce bioenergetic age and potentially slow Alzheimer’s progression. This could be a particularly beneficial approach for individuals with a high bioenergetic age but a favorable genetic profile, as they may have a greater capacity for improvement.

By improving bioenergetic capacity through these interventions, patients might lower their Alzheimer’s risk and experience fewer cognitive declines. Researchers suggest that this could be a powerful tool for prevention or even disease management in patients who are already showing early signs of Alzheimer’s.

Conclusion: A New Era for Alzheimer's Risk Assessment and Treatment

As research on bioenergetic age progresses, it has the potential to revolutionize how we approach Alzheimer’s prevention and treatment. Unlike chronological age, bioenergetic age is modifiable through lifestyle changes and early intervention. This approach could provide a personalized pathway to reducing Alzheimer’s risk and promoting brain health.

By measuring bioenergetic age and identifying individuals who may benefit from interventions to improve their energy metabolism, healthcare providers can help patients take proactive steps to protect their cognitive health. As we learn more about this fascinating concept, we may find that managing bioenergetic age could be a key tool in fighting Alzheimer’s disease and improving the quality of life for those at risk.

Learn more: https://www.nature.com/articles/s41467-025-57032-0